Response
We agree with Dr Swan that ACE inhibitors have a favorable effect on arterial compliance and central pulse pressure. We also agree that this hemodynamic effect might be associated with clinical benefit. At the same time, we again emphasize our view that ACE inhibitors by virtue of their autocrine/paracrine effect might cause regression of left ventricular hypertrophy independent of their hemodynamic properties, based on the following points.
(1) Improvement of arterial compliance and reduction of pulse pressure by antihypertensive agents is not a unique property of ACE inhibitors. Properly controlled studies, for example, have shown that the ACE inhibitor enalapril and the ␤-blocker celiprolol have similar effects in this regard, 1 as do nitrates. 2 (2) Angiotensin II is a direct growth promoter to the myocardium at doses too low to affect blood pressure. (3) In addition to its circulating form, angiotensin II is also locally produced in the heart; all components of the renin-angiotensin system have been demonstrated in the heart muscle both at mRNA levels and at protein levels. (4) ACE inhibitors can block the hypertrophic effect of angiotensin II on the myocardium without affecting blood pressure. (5) In our study, the beneficial effect of ramipril on left ventricular hypertrophy was consistent in patients with or without hypertension by history, and in patients with various blood pressure levels; it was also independent of blood pressure reduction during the study. 3 Therefore, in our study a direct antihypertrophic effect of the ACE inhibitor (over and above its effect through hemodynamic mechanisms) seems probable.
